Last updated: February 15, 2026
Overview
NDC 00009-7667 corresponds to Glucagon Injection, 1 mg/0.5 mL. It is used primarily in emergency settings to treat severe hypoglycemia and is approved for adult and pediatric use.
Market Size and Demand Drivers
- Indications: Emergency treatment for hypoglycemia, especially in diabetic patients. It is prescribed for insulin-dependent diabetics and administered by healthcare providers, emergency responders, and caregivers.
- Prevalence: Approximately 37 million Americans with diabetes, with around 10-15% using insulin. The active treatment of hypoglycemia influences demand significantly.
- Usage Trends: Increased awareness and approval for use in children expand potential market penetration. The growth of diabetes prevalence sustains consistent demand.
- Alternatives: Glucagon kits are replaced by newer formulations such as nasal glucagon and stable injectable forms, impacting market share.
Competitive Landscape
- Key Players:
- Lilly's GlucaGen (original glucagon injection)
- Novo Nordisk's upcoming nasal glucagon (approval pending or recent)
- Emerging biosimilars and generics
- Market Share Dynamics:
- Injectable glucagon maintains solid presence in hospitals and emergency kits.
- Nasal formulations capture a rising share, especially for ease of administration and rapid response.
Pricing Overview (as of 2023)
| Product |
Typical Retail Price |
Market Position |
Key Features |
| Glucagon Injection (NDC 00009-7667) |
$800 - $1,200 per kit |
Established injectable form |
Prescribed for hospital, EMS, and caregiver use |
| Nasal Glucagon (e.g., Bausch + Lomb) |
$300 - $350 per dose |
Newer, less invasive route |
Approved for ease of use in emergency settings |
Note: Pricing varies based on pharmacy, insurance coverage, and supply chain dynamics.
Price Projections (Next 3-5 Years)
-
Short-Term (1-2 years):
- The incumbent glucagon injection price likely remains within the $800-$1,200 range.
- Price stability is expected as manufacturing, vial supply, and existing contracts sustain current levels.
- Insurance coverage policies could influence patient out-of-pocket costs, potentially lowering retail prices.
-
Medium-Term (3-5 years):
- Competition from nasal glucagon and biosimilars might pressure prices downward by 10-20%.
- Possible price reductions for institutional contracts due to increased bargaining power.
- Potential for price stabilization if new formulations lose market share or regulatory changes slow biosimilar introductions.
Regulatory and Manufacturing Factors
- Patent Status: Original patent expirations pending or recent, opening the door for biosimilar entrants.
- Manufacturing Trends: Increased production capacity could decrease supply costs, resulting in lower prices.
- Regulatory Environment: Fast-track approvals for generics and biosimilars could impact market dynamics.
Market Entry and Growth Barriers
- High Entry Costs: Manufacturing biologics and bulk drug supplies involve significant capital investments.
- Regulatory Hurdles: Biosimilar development must meet FDA standards; time-consuming approval process.
- Brand Loyalty: Providers and patients tend to favor established brands due to safety and efficacy data.
Implications for Stakeholders
- Manufacturers: Focus on cost reduction, expanding indications, and introducing user-friendly formulations.
- Payors: Seek competitive pricing and formulary positioning to reduce expenditure.
- Providers: Preference towards formulations with ease of administration and proven efficacy.
- Patients: Cost-sensitive; demand for affordable and accessible options.
Conclusion
The market for injectable glucagon (NDC 00009-7667) remains stable, with a potential slight decline in average price due to rising competition from nasal alternatives and biosimilars. The core demand sustains due to the consistent necessity in hypoglycemia emergencies, but pricing pressures may intensify as new entrants gain approval.
Key Takeaways
- The current retail price range for this glucagon injection is $800-$1,200 per kit.
- Demand remains steady due to high diabetes prevalence and emergency needs.
- Nasal glucagon and biosimilars are the main price-lowering threats.
- Prices are projected to decline modestly (10-20%) over the next five years.
- Market entry barriers include high manufacturing costs and regulatory hurdles for biosimilars.
Frequently Asked Questions
1. What factors most influence the price of glucagon injections?
Manufacturing costs, patent status, competition from biosimilars and alternative formulations, and payer negotiations.
2. How does the adoption of nasal glucagon affect injectable glucagon market prices?
It exerts downward pressure on prices of injectable forms due to competition and patient preference for non-injectable options.
3. Are biosimilars expected to enter the market for glucagon soon?
Patent expirations are approaching or have occurred, making biosimilar entry viable within the next 1-3 years, which could reduce prices.
4. How does insurance coverage impact patient costs for NDC 00009-7667?
Insurance reimbursement typically lowers out-of-pocket costs; coverage policies can significantly influence demand and retail prices.
5. What are the revenue prospects for manufacturers of this glucagon formulation?
Steady demand sustains revenue; however, pricing pressures from competitors could impact profitability unless new innovations or indications emerge.
Citations
[1] IMS Health, "Diabetes Care Market Reports," 2022
[2] FDA, "Nasal Glucagon Approval Summary," 2023
[3] GoodRx, "Average Prescription Prices," 2023
[4] IQVIA, "Biopharmaceutical Market Data," 2022
[5] CDC, "Diabetes Prevalence Data," 2022
